Department of Internal Medicine and Hepatogastroenterology, University Hospital and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
Dis Esophagus. 2010 Feb;23(2):100-5. doi: 10.1111/j.1442-2050.2009.01005.x. Epub 2009 Aug 28.
Injection of botulinum toxin (BT) and pneumatic dilatation are available methods in nonsurgical treatment of achalasia. Authors anticipate beneficial effect of prior BT injection on the success of pneumatic dilatation and duration of its effect. There are no long-term data available to assess efficacy of combined treatment. From 1998 to 2007, 51 consecutive patients (20 men and 31 women, age 24-83) with achalasia were included and prospectively followed up. Each patient received injection of 200 IU of BT into the lower esophageal sphincter (LES) during endoscopy and 8 days later pneumatic dilatation (PD) under X-ray control was performed. The follow-up was established every 3 months first year and then annually. The efficacy was evaluated by a questionnaire concerning patient's symptoms and manometry. Results were compared with 40 historical controls (16 men and 24 women, age 26-80) treated by PD alone using the same method and follow-up. Fifty-one patients underwent combined treatment. Four patients failed in follow-up and were not included for analysis. The mean duration of follow-up was 48 months with range 12-96 months. Thirty-four of forty-seven (72%) patients were satisfied with results with none or very rare and mild troubles at the time of the last visit. Forty-one patients were followed up more than 2 years. Effect of therapy lasted in 75% (31/41) of them. In 17 patients, more than 5 years after treatment, effect lasted in 12 (70%). Mean tonus of LES before therapy was 29 mm Hg (10-80), 3 months after therapy decreased to 14 mmHg (5-26). The cumulative 5 years remission rate (+/-95% CI) in combined treated patients 69% +/- 8% was higher than in controls 50% +/- 9%; however it, was not statistically significant (P= 0.07). In control group 1, case of perforation (2.5%) occurred. Eight patients (17%) with relapse of dysphagia were referred to laparoscopic Heller myotomy with no surgical complication. The main adverse effect was heartburn that appeared in 17 patients (36%). Initial injection of BT followed by PD seems to be effective for long-term results with fewer complications. But the combined therapy is not significantly superior to PD alone.
肉毒杆菌毒素(BT)注射和气动扩张是非手术治疗贲门失弛缓症的可用方法。作者预计 BT 注射预先对气动扩张的成功和其效果的持续时间有有益的影响。目前尚无长期数据可评估联合治疗的疗效。1998 年至 2007 年,51 例连续贲门失弛缓症患者(20 名男性和 31 名女性,年龄 24-83 岁)纳入并前瞻性随访。每位患者均在胃镜下接受 200IU BT 注射,8 天后在 X 射线控制下进行气动扩张(PD)。第一年每 3 个月建立一次随访,然后每年一次。通过问卷调查评估患者的症状和测压术来评估疗效。结果与 40 例历史对照(16 名男性和 24 名女性,年龄 26-80 岁)进行比较,采用相同的方法和随访治疗单独进行 PD。51 例患者接受联合治疗。4 例患者失访,未纳入分析。平均随访时间为 48 个月,范围为 12-96 个月。47 例中的 34 例(72%)患者对结果满意,最后一次就诊时无或很少且轻度困扰。41 例患者随访时间超过 2 年。在 75%(31/41)的患者中,治疗效果持续存在。在 17 例患者中,治疗后 5 年以上,12 例(70%)仍有效。治疗前食管下括约肌的平均张力为 29mmHg(10-80),治疗后 3 个月降至 14mmHg(5-26)。联合治疗患者的 5 年累积缓解率(+/-95%CI)为 69% +/- 8%,高于对照组的 50% +/- 9%;但差异无统计学意义(P=0.07)。在对照组 1 中,发生穿孔(2.5%)1 例。8 例(17%)复发性吞咽困难患者行腹腔镜 Heller 肌切开术,无手术并发症。主要不良反应为烧心,17 例(36%)患者出现。初始 BT 注射后再行 PD 似乎对长期结果有效,并发症较少。但联合治疗并不明显优于单独 PD。